Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.24 (overall 0.14) | 0.24 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 2208
Sealed predictions
- ARID3B in dopamine neurons, braak+0.23 (p 0.551) → -0.35 (p 0.360)receipt 2217
Swarm cases
receipt 2217: ARID3B in dopamine neurons, braak
- power
- full sample -0.06 (p 0.800, n 18), 95% CI -0.52 to +0.42. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.664, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.05, sign flips 4; without severely affected donors -0.06 (p 0.800, n 18). fragile.
- cell type
- strongest in microglia: -0.74 (p 5.0e-4, n 18) vs -0.06 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ARID3B in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ARID3B · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.35 p 0.214 (needs p < 7.2e-4)
Receipts
loading the receipts